Q2 EPS Estimates for Aktis Oncology Raised by HC Wainwright

Aktis Oncology (NASDAQ:AKTS) – Stock analysts at HC Wainwright boosted their Q2 2026 earnings estimates for Aktis Oncology in a research report issued to clients and investors on Tuesday, June 2nd. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings of ($0.36) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.64) EPS, Q1 2027 earnings at ($0.50) EPS, Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.20) EPS.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The firm had revenue of $1.87 million for the quarter.

AKTS has been the subject of several other reports. William Blair started coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, May 26th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Aktis Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $32.50.

Aktis Oncology Price Performance

AKTS opened at $19.37 on Thursday. The firm’s 50 day moving average is $18.92. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $29.16.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.